Steady and stable transfection from lab to launch: enabling seamless viral vector scale-up

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Steady and stable transfection from lab to launch: enabling seamless viral vector scale-up

Establishing a robust and reproducible transfection process at large scale is a persistent challenge for teams manufacturing AAV and lentiviral vectors (LV). As batch volumes increase, differences in transfection complex preparation, incubation time, and transfer volume can introduce variability that impacts productivity, product quality, and development timelines. However, this has presented an opportunity for a novel solution.

This webinar examines how stabilizing transfection complex formation can support consistent performance as processes move from bench scale to clinical and commercial manufacturing. Attendees will learn how controlling continued transfection complex growth enables an expanded incubation window, supports more concentrated transfection complex preparations, and reduces the overall volume required for transfer into large production vessels. These improvements can simplify scale-up activities, reduce sensitivity to handling differences, and support more consistent productivity and product quality.

This session will also discuss practical considerations for implementing stabilized transfection workflows in large-scale manufacturing environments to streamline operations, minimize development risk, and reduce the need for repeated optimization as batch size increases.

Attend this webinar to:

Understand how transfection complex growth during incubation can impact productivity and product quality at larger manufacturing scales
Learn how stabilizing transfection complex formation can expand incubation windows and reduce sensitivity to handling variability
Explore how more concentrated transfection complex preparations can reduce transfer volumes and simplify large-scale operations
Apply practical strategies to improve transfection robustness as processes transition from early development to commercial manufacturing

Mason Bonitz

Field Application Scientist at MilliporeSigma

Mason is a Field Applications Scientist at Mirus Bio, a company committed to equipping biopharmaceutical innovators with next generation transfection solutions for all cell culture applications. Mason has 7 years of Process Development experience, primarily focusing on bioreactor scale-up and AAV transfection optimization. He has participated in bringing multiple therapeutic products from small-scale screening studies to large-scale manufacturing, leveraging his experience in process optimization and scale-up.

In 20 Days

You have registered for this webinar